Menu
Aspa Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on developing a treatment for Canavan disease, a rare and devastating genetic disorder with no FDA-approved treatment. Aspa is led by a team of veteran biotechnology executives. Working in close partnership with families and physicians, the company is committed to bringing a safe and effective treatment for Canavan disease to those who need it—without delay.
BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat Mendelian diseases—conditions caused by mutations in a single gene—and cancers with clear genetic drivers.
